Clinical and pharmacokinetic results with a new ultrashort-acting calcium antagonist, clevidipine, following gradually increasing intravenous doses to healthy volunteers

British Journal of Clinical Pharmacology

Volumn 47, Issue 5, 1999, Pages 531-538

  Ericsson, H ^a   Fakt, C ^a   Jolin Mellgard A ^a   Nordlander, M ^a   Sohtell, L ^a   Sunzel, M ^a   Rega C G ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Blood pressure reduction; Calcium antagonist; Cardiac surgery; Clevidipine; Pharmacokinetics; Population; Ultrashort acting

Indexed keywords

CALCIUM ANTAGONIST; CLEVIDIPINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HEART RATE; HEMODYNAMICS; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEAN ARTERIAL PRESSURE; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; STEADY STATE;

ADULT; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUSHING; HEADACHE; HEART RATE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; PYRIDINES; SINGLE-BLIND METHOD;

EID: 0032922805     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00933.x     Document Type: Article

References (25)

1. Vuylsteke A, Feneck R, Latimer R, et al. Type of perioperative treatment delays e.xtubation and prolongs iCU stay in cardiac surgery. Br J Anacsth 1996; 76: A30.
2. Kaplan JA, Finlayson DC, Woodward S. Vasodilator therapy after cardiac surgery: a review of the efficacy and toxicity of nitroglycerin and nitroprusside. Can Anaestli SocJ 1980; 3: 254-259.
3. Friederich JA, Dutterworth JF. Sodium nitroprusside: twenty years and counting. Anesth Analg 1995; 81: 152-162.
4. Mason DT, Braunwald E. The effect of nitroglycerin and amyl nitrite on arteriolar and venous tone in the human forearm. Circulation 1965; 32: 755.
5. Zäll S, Kirnö K, Milocco I, Ricksten S-E. Vasodilation with adenosine or sodium nitroprusside after coronary artery bypass surgery. A comperative study on myocardial blood flow and metabolism. Anesth Analg 1993; 76: 493-497.
6. Lawrence C J, Lestrade A, De Lange S. Comperative study of isradipine and sodium nitroprusside in the control of hypertension in patients following coronary artery-bypass surgery. Acta Anaestesiol Scand suppl 1993; 37: 48-52.
7. Cook E, Clifton GG, Vargas R, et al. Phannacokinetics, pharmacodynamics, and minimum effective clinical dose of intravenous nicardipinc. Clin Phannacol Tlier 1990; 47: 706-718.
8. Fakt C, StenhoffH. Determination of an ultrashort-acting antihypertcnsive dihydropyridine in blood using capillary gas chromatography mass spcctromctry and of the primary metabolite using liquid chromatography and flourescens detection. J Chromatogr B Bioincd. appL (in press).
9. Ericsson H, Tholander 13, Regårdh CG. In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolised by csterases, in different animal species and man. EnrJ Pliarin Sei (in press).
10. Yamaoka K, Nakagawa T, Uno T. Application of Akaiki's information criteria (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinct Biopharm 1976; 6: 165-175.
11. Wagner J. Linear pharmacokinetic equation allowing direct calculation of many needed pharmacokinctic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data.J Phannacokinct Biophann 1976; 4: 443-467.
12. PPHARM user's guide. 2nd ed. SIMED, Cretcil, France 1994.
13. Levy JH, Huraux C, Nordlander M. Treatment of perioperativc hypertension. In Calcium antagonists in clinical medicine, cd Epstein M. Philadelphia: Hanely and Belfus, 1997: 345-358.
14. Kieler-Jenscn N, Jolin-Mellgård Å, Nordlander M, Kicksten SE. Myocardial circulatory and metabolic effects of clevidipine after coronary artery bypass grafting (CADG) Br J Anacsth 1997; 78: A12.
15. Elvelin L, Kennerfalk A, Elmfeldt D. Tolerability and safety of felodipine. Cardiovasc Dnig Rev 1993; 11: 126-147.
16. Ericsson H, Fakt C, Höglund L, et al. Pharmacokinetics and pharmacodynamics of clevidipine in healthy volunteers after intravenous infusion. EnrJ Clin Pliarmacol (in press).
17. Benett LZ. General treatment of linear mammilary models with elimination from any compartment used in pharmacokinetics. J Pliarm Sei 1972; 61: 536-541.
18. Egan T, Lcmmcns H, Fiset P, et al. The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. Anestliesiology 1993; 79: 881-892.
19. Parivar K, Wessen A, Widman M, Nilsson A. Phannacokinetics of eltanolone following bolus and constant rate infusion. J Pliarinacokinct Biophann 1997; 24: 535-549.
20. Shafer S, Varvel J. Pharniacodynamics, and rational opioid selection. Ancslhuiology 1991; 74: 53-63.
21. Hughes M, Glass P, Jacobs J. Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. Anestheshtogy 1992; 76: 334-341.
22. Ohtake Y, Sakamoto T, Nishioka R, Uno K, Tabata S. Metabolic fate of felodipine in man. In search of new dihydropyridine metabolites. Drug Invest 1992; 4: 528-534.
23. Soons PA, Cohen AF, Breimer DD. Compcrativc effects of felodipine, nitrendipine and nifedipine in healthy subjects: concentration-effect relationships of raccmic drugs and enantiomers. EnrJ Clin Phannacol 1993; 44: 113-120.
24. Tanaka M, Nishikawa T. Arterial barorcflex function in humans anesthetized with sevofluranc. Ancsthesiology 1997; 87: A132.
25. Folkow B, Neil E. In Circulation, New York, London, Toronto: Oxford University Press, 1971.